Open AccessEfficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study
Author(s) -
Huan Gao,
Tao Tian,
Suoni Li,
Yinbin Zhang,
Xiao Fu,
Xiaoqiang Zheng,
Na Liu,
Aimin Jiang,
Mengdi Ren,
Xiaoni Zhang,
Xuan Liu,
Zhiping Ruan,
Zhimin Geng,
Yu Yao
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s290083
Subject(s) - gemcitabine , medicine , oxaliplatin , regimen , clinical endpoint , oncology , chemotherapy , gastroenterology , surgery , cancer , clinical trial , colorectal cancer
Biliary tract cancers (BTCs) have a poor overall prognosis, as patients who underwent curative surgery frequently experience disease recurrence. At present, there is a paucity of well-documented adjuvant chemotherapy regimen. This study aimed to assess whether gemcitabine plus platinum or S-1 adjuvant chemotherapy have different impact on relapse-free survival (RFS).